Balchem (BCPC) Stock Price, News & Analysis

Company Overview

Balchem Corporation, trading on the Nasdaq under the ticker BCPC, is a global specialty chemicals and nutrition company. The firm develops, manufactures and markets performance ingredients and ingredient systems that address a wide range of industries, including human and animal nutrition, food and beverage protection, pharmaceuticals and personal care. Balchem’s portfolio is built around core technologies such as advanced chelation, microencapsulation and custom ultrafine powders.

The company’s Specialty Products segment offers chelated minerals and microencapsulation solutions designed to improve nutrient delivery, stability and shelf life. Its Human Nutrition & Health segment provides ingredients and application expertise for dietary supplements, medical foods and functional beverages. Balchem’s proprietary technologies are applied to enhance flavor, protect sensitive materials and ensure precise dosage in both food and pharmaceutical formulations.

Founded in 1967 as Baltimore Chemical Company, Balchem adopted its current name in 2010 to reflect its expanded global scope and product offerings. Headquartered in New Hampton, New York, the company operates manufacturing and research facilities across North America, Europe and Asia. Balchem’s global footprint enables it to serve multinational customers and comply with regional regulatory requirements.

Under the leadership of President and Chief Executive Officer Thomas F. Coughlin, Balchem emphasizes innovation, quality and sustainability. The company invests in ongoing research and development to address emerging nutritional trends and regulatory challenges, positioning itself as a partner for customers seeking advanced ingredient solutions worldwide.

Key Stats

• Today's Range: $161.46 to $162.61
• 50-Day Range: $158.93 to $177.66
• 52-Week Range: $139.17 to $183.90
• Volume: 128,827 shs
• Average Volume: 203,171 shs
• Market Capitalization: $5.20 billion
• P/E Ratio: 33.21
• Dividend Yield: 0.59%
• Price Target: $176.00
• Consensus Rating: Buy

Balchem Stock Analysis - MarketRank™

Balchem scored higher than 49% of companies evaluated by MarketBeat, and ranked 120th out of 181 stocks in the basic materials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Buy

Consensus Rating

Balchem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Balchem is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Balchem has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 5.26%

Earnings Growth

Earnings for Balchem are expected to grow by 5.26% in the coming year, from $5.70 to $6.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Balchem is 33.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Balchem is 33.21, which means that it is trading at a more expensive P/E ratio than the Basic Materials sector average P/E ratio of about 22.97.

Price to Earnings Growth Ratio

Balchem has a PEG Ratio of 3.15. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Balchem has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the float of Balchem has been sold short.

Short Interest Ratio / Days to Cover

Balchem has a short interest ratio ("days to cover") of 1.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Balchem has recently increased by 0.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Balchem has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Balchem has been increasing its dividend for 16 years.

Dividend Coverage

The dividend payout ratio of Balchem is 19.71%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Balchem will have a dividend payout ratio of 16.00% next year. This indicates that Balchem will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Balchem this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for BCPC on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Balchem insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.39% of the stock of Balchem is held by insiders.

Percentage Held by Institutions

87.91% of the stock of Balchem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/24/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Basic Materials
• Industry: CHEM - SPECIALTY
• Sub-Industry: Specialty Chemicals
• Current Symbol: NASDAQ:BCPC
• Previous Symbol: NASDAQ:BCPC
• CIK: 9326
• Web: www.balchem.com
• Phone: (845) 326-5600
• Fax: 845-326-5717
• Employees: 1,352
• Year Founded: 1967

Price Target and Rating

• Average Price Target for Balchem: $176.00
• High Price Target: $190.00
• Low Price Target: $162.00
• Potential Upside/Downside: +8.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.87
• Trailing P/E Ratio: 33.21
• Forward P/E Ratio: 28.38
• P/E Growth: 3.15
• Net Income: $154.85 million
• Net Margins: 14.95%
• Pretax Margin: 19.26%
• Return on Equity: 13.38%
• Return on Assets: 10.17%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 2.55
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $1.04 billion
• Price / Sales: 5.01
• Cash Flow: $6.59 per share
• Price / Cash Flow: 24.53
• Book Value: $40.00 per share
• Price / Book: 4.04

Miscellaneous

• Outstanding Shares: 32,130,000
• Free Float: 31,683,000
• Market Cap: $5.20 billion
• Optionable: Optionable
• Beta: 0.85